Search

Your search keyword '"Volkov, A."' showing total 20 results
Start Over Author "Volkov, A." Language hebrew
20 results on '"Volkov, A."'

20. [Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders].

Author

Lozinski A, Baum S, Sagi L, Volkov A, Trau H, and Barzilai A

Subjects
Adult, Anemia, Hemolytic chemically induced, Anti-Infective Agents administration & dosage, Anti-Infective Agents adverse effects, Biopsy, Dapsone administration & dosage, Dapsone adverse effects, Drug Resistance, Female, Fluorescent Antibody Technique, Direct methods, Glucocorticoids administration & dosage, Humans, Immunologic Factors administration & dosage, Prednisone administration & dosage, Pregnancy, Pruritus etiology, Rare Diseases drug therapy, Rare Diseases immunology, Rare Diseases pathology, Rare Diseases physiopathology, Rituximab, Severity of Illness Index, Skin drug effects, Treatment Outcome, Antibodies, Monoclonal, Murine-Derived administration & dosage, Linear IgA Bullous Dermatosis drug therapy, Linear IgA Bullous Dermatosis immunology, Linear IgA Bullous Dermatosis pathology, Linear IgA Bullous Dermatosis physiopathology, Pemphigoid Gestationis drug therapy, Pemphigoid Gestationis immunology, Pemphigoid Gestationis pathology, Pemphigoid Gestationis physiopathology, Skin pathology
Abstract

Autoimmune bullous skin disorders are characterized by a severe and potentially lethal course and may require aggressive long-term treatment with systemic corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Recently, anti-CD20 antibody, Rituximab, was reported to be beneficial as an adjuvant therapy in these diseases. Herein, we present 2 case reports of patients suffering from resistant rare diseases from the aforementioned spectrum: linear IgA dermatosis and Pemphigoid gestationis. The patients were successfully treated with Rituximab (Mabthera). This is one of the first reports of this kind of treatment for these rare life-threatening diseases. These case reports emphasize the role of Rituximab as a crisis therapy in autoimmune blistering diseases.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results